Key Points
- NAD+ increased the number of mature eggs retrieved
- More eggs were successfully fertilized
- Number of top-quality (Grade A) embryos more than doubled
- Benefits observed in both younger (<35 years) and older (โฅ35 years) groups
What the Study Looked At
The study followed 112 women with diminished ovarian reserve, meaning they usually produce fewer eggs during IVF.
Each woman completed:
- One IVF cycle before receiving NAD+, and
- One IVF cycle after completing NAD+ treatment
Treatment protocol
- IV NAD+: 200 units once per week
- Duration: 10 weeks
- IVF stimulation and lab protocols were kept exactly the same before and after treatment
This design allowed researchers to compare each woman to herself, rather than comparing different people.
NAD+ Increased Egg Quality & Quantity
After IV NAD+ therapy, the number of mature eggs increased from about 4 to 6 per IVF cycle, nearly a 50% increase in eggs ready for fertilization.
"Significant improvement was observed in the number of mature metaphase II (MII) oocytes retrieved following NAD+ therapyโฆ Yield increased from 4.06 in the pre-treatment cycle to 6.06 in the post-treatment cycle."
This suggests the treatment helped existing eggs mature and function better, rather than simply increasing the number of follicles stimulated, especially important for women who already have a limited egg supply.
Similar data have been observed in animal models, where restoring NAD+ levels improved ovarian function and oocyte integrity, highlighting the role of NAD+ pathways in reproductive aging.
50% Increase in Successfully Fertilized Eggs
The number of normally fertilized embryos similarly rose from 3.75 before treatment to 5.75 after treatment.
"Normally fertilized oocytes exhibiting two pronuclei increased significantly from 3.75 before NADโบ therapy to 5.75 after therapy, corresponding to a mean increase of 2.00 fertilized oocytesโฆ"
Because the number of mature eggs and the number of fertilized embryos increased together, this indicates that the additional eggs were healthy and capable of normal fertilization, not just present in greater numbers.
Top Quality Embryos More Than Doubled
The largest improvements were seen in embryo quality.
- Grade A embryos increased from 1.62 to 4.31 per cycle
- Overall good-quality embryos more than doubled
"Grade A embryos are associated with superior developmental potential, and the magnitude of this improvement suggests that NADโบ therapy may preferentially enhance intrinsic oocyte and embryo competence rather than simply increasing embryo quantity."
These results suggest that IV NAD+ not only helped produce more eggs but increased the quality of embryos, especially important for IVF success.
Conclusion
This study shows IV NAD+ significantly improves reproductive egg quality, quantity, and multistage support of the reproductive process, in women with diminished ovarian reserve.
This study shows that IV NADโบ was associated with meaningful improvements in egg maturity, fertilization, and early embryo quality in women with diminished ovarian reserve.
"This data demonstrated a consistent pattern of improvement across successive stages of early reproductive development following NADโบ therapyโฆ"
"Increases in mature oocyte yields were accompanied by improved fertilization and translated into a significantly higher number of high-quality cleavage-stage embryos."
This human IVF study demonstrates that directly raising NADโบ levels in the bloodstream can produce meaningful biological effects, reinforcing the importance of effective NADโบ delivery strategies rather than reliance on precursor conversion alone.
This observation is supported by prior clinical evidence showing that intravenous NADโบ leads to rapid and substantial increases in circulating NADโบ levels, underscoring why delivery route may be critical for therapeutic outcomes.
Together, these findings strengthen the case for NADโบ as an active biomolecule, not merely a precursor-dependent intermediate, and support continued exploration of NADโบ delivery strategies in human health.
Findings should be interpreted as preliminary but meaningful human evidence, not definitive proof of clinical success. Larger randomized trials evaluating downstream reproductive outcomes are still needed.
